Artelo Biosciences, Inc.
ARTL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1,275 | $1,871 | $1,384 | $2,476 |
| G&A Expenses | $1,814 | $1,279 | $995 | $1,336 |
| SG&A Expenses | $1,814 | $1,279 | $995 | $1,336 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3,089 | $3,150 | $2,379 | $3,812 |
| Operating Income | -$3,089 | -$3,150 | -$2,379 | -$3,812 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$31 | -$71 | $7 | $34 |
| Pre-Tax Income | -$3,120 | -$3,221 | -$2,372 | -$3,778 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3,120 | -$3,221 | -$2,372 | -$3,778 |
| % Margin | – | – | – | – |
| EPS | -3.97 | -5.61 | -0.72 | -7 |
| % Growth | 29.2% | -679.2% | 89.7% | – |
| EPS Diluted | -3.97 | -5.61 | -0.72 | -7 |
| Weighted Avg Shares Out | 787 | 574 | 3,281 | 540 |
| Weighted Avg Shares Out Dil | 787 | 574 | 3,281 | 540 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $1 | $7 | $0 |
| Interest Expense | $111 | $72 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$3,009 | -$3,149 | -$2,379 | -$3,812 |
| % Margin | – | – | – | – |